The current status of immunobased therapies for metastatic renal-cell carcinoma

Niranjan J Sathianathen; Suprita Krishna; J Kyle Anderson; Christopher J Weight; Shilpa Gupta; Badrinath R Konety; Thomas S Griffith

doi:10.2147/ITT.S134850

The current status of immunobased therapies for metastatic renal-cell carcinoma

Niranjan J Sathianathen, Suprita Krishna, J Kyle Anderson, Christopher J Weight, Shilpa Gupta, Badrinath R Konety, Thomas S Griffith

Research output: Contribution to journal › Article › peer-review

Abstract

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

Original language	English (US)
Pages (from-to)	83-93
Number of pages	11
Journal	ImmunoTargets and Therapy
Volume	Volume 6
DOIs	https://doi.org/10.2147/ITT.S134850
State	Published - 2017

Keywords

cryosurgery
immunocheckpoints
immunotherapy
kidney neoplasm
targeted therapy
vaccines

PubMed: MeSH publication types

Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.2147/ITT.S134850

OpenUrl availability

Full text

Cite this

@article{216c33297d404ed88114dbd57ede5384,

title = "The current status of immunobased therapies for metastatic renal-cell carcinoma",

abstract = "The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.",

keywords = "cryosurgery, immunocheckpoints, immunotherapy, kidney neoplasm, targeted therapy, vaccines",

author = "Sathianathen, {Niranjan J} and Suprita Krishna and Anderson, {J Kyle} and Weight, {Christopher J} and Shilpa Gupta and Konety, {Badrinath R} and Griffith, {Thomas S}",

year = "2017",

doi = "10.2147/ITT.S134850",

language = "English (US)",

volume = "Volume 6",

pages = "83--93",

journal = "ImmunoTargets and Therapy",

issn = "2253-1556",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The current status of immunobased therapies for metastatic renal-cell carcinoma

AU - Sathianathen, Niranjan J

AU - Krishna, Suprita

AU - Anderson, J Kyle

AU - Weight, Christopher J

AU - Gupta, Shilpa

AU - Konety, Badrinath R

AU - Griffith, Thomas S

PY - 2017

Y1 - 2017

N2 - The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

AB - The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

KW - cryosurgery

KW - immunocheckpoints

KW - immunotherapy

KW - kidney neoplasm

KW - targeted therapy

KW - vaccines

U2 - 10.2147/ITT.S134850

DO - 10.2147/ITT.S134850

M3 - Article

C2 - 29255699

SN - 2253-1556

VL - Volume 6

SP - 83

EP - 93

JO - ImmunoTargets and Therapy

JF - ImmunoTargets and Therapy

ER -

The current status of immunobased therapies for metastatic renal-cell carcinoma

Abstract

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Fingerprint

Cite this